The failure of a Cotellic/Tecentriq combo in the IMblaze370 trial highlights Exelixis' dependence on its renal cell carcinoma drug CaboMetyx...
Original Article: Exelixis' Cotellic Fails To IMblaze A Trail In Colorectal Cancer